Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00192231
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : September 13, 2021
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
MedImmune LLC

Brief Summary:
The primary objective of this study was to perform a variety of immunological assays on blood, serum, nasal wash samples, and cells obtained from healthy adult subjects for the purpose of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T).

Condition or disease Intervention/treatment Phase
Influenza Biological: CAIV-T Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 and Older
Study Start Date : April 2001
Study Completion Date : June 2001

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The safety objective was to assess the safety and tolerability of CAIV-T vaccine.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adults aged 18 to 59 years or > 60 years.
  • Female subjects of childbearing potential who had a negative urine pregnancy test result prior to study vaccination. Females who were surgically sterilized or post-menopausal did not require pregnancy testing.
  • Adults who were determined by medical history, physical examination and clinical judgment eligible for this study. Subjects with stable pre-existing disease, defined as disease not requiring change in therapy or hospitalization within 12 weeks before receipt of study vaccination, were eligible.
  • Subjects who provided written informed consent after the nature of the study was explained.
  • Subjects who were available for the duration of the study (from enrollment to study completion).
  • Subjects who could be reached by study staff for the post-vaccination contact [via telephone, clinic or home visit].

Exclusion Criteria:

  • Subjects who resided in a nursing home or long-term care facility or other institution receiving skilled or semi-skilled nursing care. An ambulatory subject who resided in a retirement home or village was eligible for participation.
  • Subjects with evidence of dementia or other severe cognitive impairment based on Mini Mental State Examination (MMSE) score of 22 or greater. Note: Administration of MMSE was performed only if clinically indicated.

For all study subjects:

  • Subjects who were perceived to be unavailable or difficult to contact for evaluation of study visits during the study period.
  • Subjects with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents.
  • Subjects who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study.
  • Subjects who resided in the same household as an immunosuppressed or immunocompromised individual.
  • Subjects with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo.
  • Subjects who were administered any live virus vaccine within one month prior to enrollment.
  • Subjects for whom there was intent to administer any other investigational vaccine or agent from one month prior to enrollment through the conclusion of the study.
  • Subjects who received a dose of influenza treatment (commercial or investigational) one month prior to enrollment. Prophylactic use of influenza antivirals was not permitted.
  • Subjects who received any influenza vaccine in the six months prior to enrollment, or nonstudy influenza vaccine since enrollment.
  • Subjects with any medical conditions that in the opinion of the investigator might interfere with the interpretation of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00192231

Layout table for location information
Australia, Victoria
Austin & Repatriation Medical Centre
Heidelburg, Victoria, Australia, 3084
Sponsors and Collaborators
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer
Layout table for investigator information
Study Director: Robert Walker, MD MedImmune LLC
Layout table for additonal information Identifier: NCT00192231    
Other Study ID Numbers: D153 P510
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: September 13, 2021
Last Verified: October 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases